Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

Sorafenib in Advanced Hepatocellular Carcinoma | Synapse

July 23, 2008Open Access

Sorafenib in Advanced Hepatocellular Carcinoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Llovet et al. (Wed,) studied this question.

synapsesocial.com/papers/69d6d84e8dca315383ed93ac https://doi.org/https://doi.org/10.1056/nejmoa0708857

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma1994 · 128 citations
2Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein2006 · 56 citations
3The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC)2007 · 62 citations
4Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.2017 · 22 citations
5When Does the Presence of the Target Predict Response to the Targeted Agent?2005 · 31 citations